MASH

London, UK, September 3, 2026 Tangram Therapeutics announced that its investigational MASH treatment TGM-312 has progressed into Part B...

Daix, France and New York, September 2, 2026 Inventiva announced that the last patient has completed the final 72-week...

RAMAT GAN, Israel, September 2, 2026 Can-Fite BioPharma Ltd. reported that blinded overall survival observed across the entire patient...

GAITHERSBURG, Md., Aug. 3, 2026 Altimmune, Inc. has initiated patient enrollment in the global PERFORMA Phase 3 registrational trial...

GAITHERSBURG, Md., July 28, 2026 Altimmune, Inc. announced positive topline results from its Phase 2 RECLAIM clinical trial evaluating...

RAMAT GAN, Israel, July 20, 2026 Can-Fite BioPharma Ltd. (NYSE American: CANF) announced that positive Phase 2a clinical trial...

CONSHOHOCKEN, Pa., July 13, 2026 Madrigal Pharmaceuticals announced that the U.S. Patent and Trademark Office (USPTO) has issued three...

CAMBRIDGE, Mass. | July 9, 2026 MetaVia Inc., a clinical-stage biotechnology company focused on developing innovative therapies for cardiometabolic...

Lille, France; Cambridge, Massachusetts, United States; and Zurich, Switzerland, July 2, 2026 GENFIT announced that U.S. Medicare has approved...

CAMBRIDGE, Mass., June 24, 2026 Wave Life Sciences announced the initiation of the Phase 2a multidose portion of the...